Immune Modulating Drugs in Viral Infections
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1896
Special Issue Editor
2. Junglock Biomedical Institute, Daejeon, Republic of Korea
Interests: immunopathogenesis and etiological substances; early use of immune modulators (corticosteroids and other drugs) in viral infections
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
At the present time, the pathophysiology of acute target-cell injury and a variety of clinical manifestations in viral infections, including COVID-19 and influenza, need to be further evaluated. During the COVID-19 pandemic, it was reported that immune-modulators, especially corticosteroids, reduce the morbidity and mortality of severely affected patients. Now, it is known that host immune systems react not only to pathogens but also to the substances originating from the pathogens, including toxins and pathogen-associated molecular patterns (PAMPs), and those originating from injured or infected host cells, including damage (danger)-associated molecular patterns (DAMPs), pathogenic proteins, and pathogenic peptides. In any viral infection, the host’s hyperactive or aberrant immune response to acute infectious insults, such as cytokine storm, may be related to host cell injury, and substances produced by injured target cells can induce even greater inflammation if they are released into the systemic circulation or local environment. Therefore, it is crucial to control initial hyperactive immune responses to reduce morbidity and prevent disease progression, and the early use of immune modulators such as corticosteroids, intravenous immunoglobulin and biologics has a basis for treating patients with acute severe viral infection. This Special Issue welcomes original or review articles and case reports related to any aspect of the use of immune-modulators for patients with viral infections, including COVID-19, and studies on pathogenesis, PAMPs, and DAMPs in viral infections.
Dr. Kyung-Yil Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- pathogenesis
- immune modulators
- corticosteroids
- intravenous immunoglobulin
- biologics
- pathogen-associated molecular patterns (PAMPs)
- damage (danger)-associated molecular patterns (DAMPs)
